The colon has emerged as an optimal site for the oral delivery of drugs targeting inflammatory bowel diseases (IBDs) including Ulcerative Colitis (UC), Crohn’s disease (CD), Amebiosis or colonic cancer. The overall goal of colonic delivery is to achieve high drug concentrations that optimize localized absorption by reducing intestinal metabolic activity for acid and enzymatically labile products including proteins and peptides. While colon delivery has been an area of market focus for many decades, new approaches have recently been developed that combine pH, time or microbial-dependent systems into single or dual-coating layers for use with various oral solid dosage forms.
Please check the highlighted fields and try again.
Please fill out the information below. If you are already registered, login and this information will be filled out for you.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.
Please enter the phone number you would like to be contacted at.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.